PDB18 THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE-AN ECONOMIC EVALUATION PROJECTING RESULTS FROM A CLINICAL STUDY INTOTHE FUTURE USING AVALID AND RELIABLE ECONOMIC MODEL FROM ATHIRD PARTY PAYER PERSPECTIVE IN THE USA

Nov 1, 2007, 00:00
10.1016/S1098-3015(10)64966-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)64966-2/fulltext
Title : PDB18 THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE-AN ECONOMIC EVALUATION PROJECTING RESULTS FROM A CLINICAL STUDY INTOTHE FUTURE USING AVALID AND RELIABLE ECONOMIC MODEL FROM ATHIRD PARTY PAYER PERSPECTIVE IN THE USA
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64966-2&doi=10.1016/S1098-3015(10)64966-2
First page :
Section Title :
Open access? : No
Section Order : 126
Categories :
Tags :
Regions :
ViH Article Tags :